Psilocybin has returned to the scientific stage with compelling early results for depression, PTSD, anxiety and addiction. Teams at Johns Hopkins, Imperial College London and MAPS have all shown that short, well‑supported courses of treatment can relieve suffering for some people. Yet the closer we look, the more we see how much we still don’t know—especially if we want to move beyond symptom relief toward whole‑person healing.
“Psilocybin leads to a profound shift in brain connectivity. Fixed networks are dissolved and new communication pathways are created.” — Dr Nicholas Fabiano
At the centre of these open questions sits a single idea: neuroplasticity. The brain is not a fixed machine but a living network that rewires with experience. When this plasticity is guided in a healthy environment, people often learn, recover and grow; when it is driven by stress, inflammation or isolation, plasticity can just as easily consolidate anxiety, rumination and addictive loops. Understanding how psilocybin interacts with plasticity—and how to prepare the “soil” so new wiring takes root—is the bridge between promising trials and durable, equitable outcomes.
Long‑term outcomes remain our first blind spot. Most studies follow people for weeks or a few months after dosing. We still do not know who maintains benefit at 12–24 months, who relapses, who needs a top‑up session and who is destabilised without robust integration. Classic trials have demonstrated meaningful short‑term gains (for example in cancer‑related depression and anxiety), but they also underline how urgently we need longer follow‑up and clearer maintenance pathways to judge true therapeutic value beyond the initial glow.
A second gap concerns prediction. Two people can sit in the same room, take the same dose and have opposite trajectories—one toward relief, the other toward disequilibrium. Pre‑existing traits, trauma exposure, personality, sleep and hormonal status, even social safety, likely shape outcomes, but we do not yet have reliable clinical tools to anticipate response. This is where the biology of plasticity begins to matter. Brain‑derived neurotrophic factor (BDNF)—sometimes called Miracle‑Gro for neurons—supports synapse growth and learning, especially in the hippocampus. Higher BDNF is associated with cognitive flexibility; lower levels track with depression and neurodegeneration. Genetics also play a role: common variants such as BDNF Val66Met can blunt activity‑dependent BDNF release and may change how people respond to therapy.
The third missing piece is inclusion. People with bipolar disorder, psychosis‑spectrum conditions or current substance‑induced instability are usually excluded from trials, yet in the real world they may be the first to self‑experiment. Without careful studies, we cannot design harm‑reduction pathways, understand interactions with SSRIs or antipsychotics, or create stepped‑care models that meet these patients where they are. Equity requires protocols, not guesswork.
We also know surprisingly little about the gut–brain axis in psychedelic care. More than ninety percent of the body’s serotonin is made in the gut, and microbial metabolites continuously signal to the brain via immune, endocrine and vagal pathways. Chronic inflammation suppresses BDNF and narrows plasticity; dysbiosis and ultra‑processed diets appear to push the nervous system toward rigidity. Trials rarely evaluate diet, microbiome status or inflammatory load before dosing, even though these factors could shape the intensity and stability of the therapeutic window that follows.
Integration is another under‑measured determinant of success. The acute experience may dissolve rigid loops and increase network flexibility, but the weeks that follow are where new habits, beliefs and relationships are actually rehearsed and installed. Bodywork, breath practices, journalling, group sharing and time in nature all appear to help people translate insights into daily life, yet few studies track these practices or compare integration frameworks.
Indigenous knowledge has long treated set, setting and community as medicine. Sacred intention, ritual, song and periods of dietary preparation can lower stress physiology, deepen trust and coordinate group states—conditions that are friendly to BDNF‑supported learning. Ethically engaging with these traditions—without extraction or appropriation—could improve safety and outcomes while honouring the lineages that stewarded these tools.
Methodologically, psychedelic science still wrestles with placebo and expectation. Because the altered state is obvious, blinding is fragile; therapist presence and group energy influence outcomes but are seldom measured as primary variables. Smarter trial designs and active placebos help, but we also need ways to quantify relational and contextual forces rather than treating them as noise.
What, then, does modern neuroscience add? Foundational work on “neurons that fire together wire together” explains why emotionally salient experiences can rapidly reconfigure networks. Preclinical research shows that classic psychedelics can increase dendritic spine growth and synaptic strength and quickly raise BDNF expression, creating a window in which new learning is unusually sticky. Human imaging studies complement this biology. Using topological analyses of functional networks, researchers have shown that psilocybin temporarily increases the diversity and reach of brain‑wide communication patterns—more exploratory, less locked in—before the system settles into a new, and sometimes healthier, organisation. These findings converge on the same story: psilocybin appears to reopen plasticity. What we do with that window determines whether change heals or harms.
Because plasticity is a gatekeeper, the terrain matters as much as the tool.
Sleep deepens memory consolidation and supports BDNF; even a single night of poor sleep can blunt learning the next day. Aerobic exercise increases hippocampal volume and elevates BDNF in a dose‑responsive fashion. Anti‑inflammatory dietary patterns rich in omega‑3s, polyphenols and fibre appear to shift the microbiome and immune tone toward resilience, while ultra‑processed foods and chronic stress move it the other way. Psychotherapies such as CBT and trauma‑informed approaches give people the behavioural scaffolding to rehearse new patterns while the brain is most malleable. Breathwork, active meditation, neurofeedback and time in green spaces can calm the limbic system and stabilise gains. In short, we can prepare the ground so that when the psychedelic wind blows, the seeds take root.
This perspective also reframes familiar clinical questions. Rather than asking only “what dose?” we might ask “what dose, in what body, with what sleep, diet, movement, relationships and supports, and for how long afterwards?” We might evaluate not just symptom scores but also inflammatory markers, sleep architecture, heart‑rate variability, diet quality and social connection. We might look for biological and psychological signatures that tell us when the window is open and how to keep it open just long enough for safer rewiring.
There is still much to learn at the molecular and systems level. How do changes in the default mode and salience networks translate into durable shifts in mood and behaviour? How do serotonin, glutamate and dopamine dynamics interact with BDNF‑TrkB signalling across days and weeks? Can we reopen selected “critical periods” in adults—as shown for social reward learning with other agents—and then close them deliberately with sleep, nutrition and gentle routine to protect fragile gains? The answers will make protocols more precise and reduce unnecessary risk.
Safety and access
Psychedelics can destabilise as well as liberate. People with a history of mania or psychosis, those on complex medication regimens, or those under heavy life stress may need slower, more supported pathways—or non‑drug routes to similar ends. The good news is that many routes exist. Structured exercise, high‑quality sleep, anti‑inflammatory nutrition, trauma‑informed therapy and active meditation can all increase plasticity and reduce suffering with minimal risk. For some, these will be sufficient; for others, they are the foundation that makes psychedelic work safer and more effective.
What you can do now, practically speaking, is straightforward. In the week before any deep work, protect your nights: go to bed at a consistent time and let mornings unfold without alarms when possible. Move your body most days, favouring steady‑state cardio with a sprinkling of short, intense efforts if you feel robust. Eat close to the land: plenty of colourful plants, quality proteins and omega‑3‑rich fats; avoid ultra‑processed foods and limit sugar and alcohol. Tend your gut with fibre‑rich foods and, if tolerated, fermented vegetables. Set clear intentions in writing. Line up integration support in advance—someone to talk to, a bodywork session, a walk in the woods.
If you are on psychiatric medication or live with complex health conditions, consult your clinician and consider extending the preparation and integration phases, or exploring non‑drug pathways first.
For researchers, the invitation is to treat plasticity not as a background concept but as a measurable, modifiable engine of change. Include sleep, diet and inflammatory assessments in trials. Stratify by microbiome patterns and BDNF‑related genotypes. Compare integration frameworks head‑to‑head. Build harm‑reduction protocols for people who are currently excluded from studies but present in real life. And keep learning from communities that have carried this work for generations.
If you’re looking for a practical way to build the “terrain” for any deep work—psychedelic or not—the starting point is clear: prioritize sleep, movement, anti‑inflammatory nutrition, and supportive integration practices. These actions directly support brain‑derived neurotrophic factor (BDNF) and healthy neuroplasticity, which research links to greater resilience and improved outcomes.
Active meditations are one of the most accessible ways to naturally enhance plasticity. Techniques that combine breathwork, focused movement, and intention setting have been shown to stabilize the nervous system and reinforce new neural pathways over time.
➡️ If you want a practical entry point into prevention and terrain‑building, start here: Overcoming Fear of Infections: Natural Strategies to Strengthen Immunity . https://www.jascotee.com/blogs/news/overcoming-fear-of-infections-natural-strategies-to-strengthen-immunity?_pos=1&_sid=8dbc614ae&_ss=r Try my guided active meditations, designed to help you create lasting neural change and emotional balance naturally. These practices complement psychedelic and non‑psychedelic therapies alike by preparing your brain and body for growth.
Book a session or join a live active meditation with me to experience the difference firsthand.
References
Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life‑threatening cancer: a randomized double‑blind trial. J Psychopharmacol. 2016.
Carhart‑Harris RL, et al. Psilocybin with psychological support for treatment‑resistant depression: six‑month follow‑up. Psychopharmacology. 2018.
Studerus E, et al. Acute, subacute and long‑term subjective effects of psilocybin in healthy volunteers. J Psychopharmacol. 2011.
Petri G, et al. Homological scaffolds of brain functional networks. R Soc Interface. 2014.
Ly C, et al. Psychedelics promote structural and functional neural plasticity. Cell Reports. 2018.
Casarotto PC, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021.
Cryan JF, Dinan TG. Mind‑altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012.
Erickson KI, et al. Exercise training increases size of hippocampus and improves memory. PNAS. 2011.
Szigeti B, et al. Self‑blinding citizen science to explore psychedelic microdosing. eLife. 2021.
Gorman I, et al. Psychedelic integration: an analysis of the concept and its practice. Front Psychol. 2021.
Erickson et al., 2011; Ly et al., 2018; Casarotto et al., 2021
Gorman et al., 2021
